ABIVAX Société Anonyme (NASDAQ:ABVX - Get Free Report)'s stock price gapped down before the market opened on Tuesday . The stock had previously closed at $7.90, but opened at $7.68. ABIVAX Société Anonyme shares last traded at $7.92, with a volume of 11,755 shares trading hands.
Wall Street Analysts Forecast Growth
Several analysts recently issued reports on ABVX shares. JMP Securities started coverage on ABIVAX Société Anonyme in a research note on Wednesday, December 4th. They issued an "outperform" rating and a $33.00 target price on the stock. Citizens Jmp raised ABIVAX Société Anonyme to a "strong-buy" rating in a research note on Wednesday, December 4th. One equities research analyst has rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat, ABIVAX Société Anonyme currently has a consensus rating of "Buy" and an average target price of $38.67.
View Our Latest Research Report on ABIVAX Société Anonyme
ABIVAX Société Anonyme Stock Up 0.5 %
The company has a 50 day moving average of $9.40 and a two-hundred day moving average of $11.23.
Institutional Investors Weigh In On ABIVAX Société Anonyme
Hedge funds have recently bought and sold shares of the business. BNP Paribas Financial Markets raised its position in shares of ABIVAX Société Anonyme by 82.6% in the 3rd quarter. BNP Paribas Financial Markets now owns 13,044 shares of the company's stock worth $150,000 after purchasing an additional 5,900 shares during the last quarter. Walleye Capital LLC lifted its stake in shares of ABIVAX Société Anonyme by 45.8% in the third quarter. Walleye Capital LLC now owns 257,417 shares of the company's stock worth $2,965,000 after buying an additional 80,807 shares in the last quarter. Point72 Asset Management L.P. grew its holdings in shares of ABIVAX Société Anonyme by 28.2% during the third quarter. Point72 Asset Management L.P. now owns 542,900 shares of the company's stock valued at $6,254,000 after buying an additional 119,300 shares during the last quarter. Finally, abrdn plc increased its position in shares of ABIVAX Société Anonyme by 167.7% during the third quarter. abrdn plc now owns 316,431 shares of the company's stock valued at $3,645,000 after acquiring an additional 198,225 shares in the last quarter. Institutional investors own 47.91% of the company's stock.
About ABIVAX Société Anonyme
(
Get Free Report)
ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.
See Also
Before you consider ABIVAX Société Anonyme, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ABIVAX Société Anonyme wasn't on the list.
While ABIVAX Société Anonyme currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
As the AI market heats up, investors who have a vision for artificial intelligence have the potential to see real returns. Learn about the industry as a whole as well as seven companies that are getting work done with the power of AI.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
